Youngun Kim
YOU?
Author Swipe
View article: Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study
Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study Open
Background Immune checkpoint inhibitor (ICI) monotherapy elicits limited intrahepatic responses in patients with advanced hepatocellular carcinoma (HCC). Here, we investigate the organ‐specific objective response rate (OSORR) of nivolumab …
View article: Epidemiology and genomic features of biliary tract cancer and its unique features in Korea
Epidemiology and genomic features of biliary tract cancer and its unique features in Korea Open
Biliary tract cancer (BTC) is a rare but highly aggressive malignancy that includes intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma, and gallbladder cancer (GBC). While BTC has a low global incidence, its regional va…
View article: Distinct Characteristics and Changes in Liver Function of Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab for more than 1 Year
Distinct Characteristics and Changes in Liver Function of Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab for more than 1 Year Open
The Ate/Bev long-term treatment group had a lower intrahepatic tumor burden, less portal vein tumor thrombosis, and better performance status and liver function at baseline. Atezolizumab-related immunological adverse events emerged relativ…
View article: Distinct characteristics and changes in liver function of patients with HCC treated with Ate/Bev for more than 1 year
Distinct characteristics and changes in liver function of patients with HCC treated with Ate/Bev for more than 1 year Open
Background/Aims: Since 2020, Atezolizumab plus bevacizumab (Ate/Bev) has been the standard first-line therapy for unresectable hepatocellular carcinoma (HCC), but long-term treatment studies are limited. This study evaluated the clinical c…
View article: Supplementary Table S4 from PD-1 Blockade Reinvigorates Bone Marrow CD8<sup>+</sup> T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
Supplementary Table S4 from PD-1 Blockade Reinvigorates Bone Marrow CD8<sup>+</sup> T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors Open
Supplementary Table S4
View article: Supplementary Figures S1-S21 from PD-1 Blockade Reinvigorates Bone Marrow CD8<sup>+</sup> T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
Supplementary Figures S1-S21 from PD-1 Blockade Reinvigorates Bone Marrow CD8<sup>+</sup> T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors Open
Supplementary Figures S1-S21
View article: Supplementary Table S1 from PD-1 Blockade Reinvigorates Bone Marrow CD8<sup>+</sup> T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
Supplementary Table S1 from PD-1 Blockade Reinvigorates Bone Marrow CD8<sup>+</sup> T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors Open
Supplementary Table S1
View article: Data from PD-1 Blockade Reinvigorates Bone Marrow CD8<sup>+</sup> T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
Data from PD-1 Blockade Reinvigorates Bone Marrow CD8<sup>+</sup> T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors Open
Purpose:Immune-checkpoint inhibitors have shown therapeutic efficacy in various malignant diseases. However, anti-programmed death (PD)-1 therapy has not shown clinical efficacy in multiple myeloma.Experimental Design:Bone marrow (BM) mono…
View article: Supplementary Table S1 from PD-1 Blockade Reinvigorates Bone Marrow CD8<sup>+</sup> T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
Supplementary Table S1 from PD-1 Blockade Reinvigorates Bone Marrow CD8<sup>+</sup> T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors Open
Supplementary Table S1
View article: Supplementary Table S2 from PD-1 Blockade Reinvigorates Bone Marrow CD8<sup>+</sup> T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
Supplementary Table S2 from PD-1 Blockade Reinvigorates Bone Marrow CD8<sup>+</sup> T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors Open
Supplementary Table S2
View article: Supplementary Table S3 from PD-1 Blockade Reinvigorates Bone Marrow CD8<sup>+</sup> T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
Supplementary Table S3 from PD-1 Blockade Reinvigorates Bone Marrow CD8<sup>+</sup> T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors Open
Supplementary Table S3
View article: Data from PD-1 Blockade Reinvigorates Bone Marrow CD8<sup>+</sup> T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
Data from PD-1 Blockade Reinvigorates Bone Marrow CD8<sup>+</sup> T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors Open
Purpose:Immune-checkpoint inhibitors have shown therapeutic efficacy in various malignant diseases. However, anti-programmed death (PD)-1 therapy has not shown clinical efficacy in multiple myeloma.Experimental Design:Bone marrow (BM) mono…
View article: Supplementary Table S2 from PD-1 Blockade Reinvigorates Bone Marrow CD8<sup>+</sup> T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
Supplementary Table S2 from PD-1 Blockade Reinvigorates Bone Marrow CD8<sup>+</sup> T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors Open
Supplementary Table S2
View article: Supplementary Table S4 from PD-1 Blockade Reinvigorates Bone Marrow CD8<sup>+</sup> T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
Supplementary Table S4 from PD-1 Blockade Reinvigorates Bone Marrow CD8<sup>+</sup> T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors Open
Supplementary Table S4
View article: Supplementary Data from PD-1 Blockade Reinvigorates Bone Marrow CD8<sup>+</sup> T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
Supplementary Data from PD-1 Blockade Reinvigorates Bone Marrow CD8<sup>+</sup> T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors Open
Legend for supplementary data
View article: Supplementary Table S3 from PD-1 Blockade Reinvigorates Bone Marrow CD8<sup>+</sup> T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
Supplementary Table S3 from PD-1 Blockade Reinvigorates Bone Marrow CD8<sup>+</sup> T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors Open
Supplementary Table S3
View article: Supplementary Data from PD-1 Blockade Reinvigorates Bone Marrow CD8<sup>+</sup> T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
Supplementary Data from PD-1 Blockade Reinvigorates Bone Marrow CD8<sup>+</sup> T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors Open
Legend for supplementary data
View article: Supplementary Figures S1-S21 from PD-1 Blockade Reinvigorates Bone Marrow CD8<sup>+</sup> T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
Supplementary Figures S1-S21 from PD-1 Blockade Reinvigorates Bone Marrow CD8<sup>+</sup> T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors Open
Supplementary Figures S1-S21
View article: High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma
High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma Open
Immune checkpoint inhibitor (ICI) became a standard treatment for advanced renal cell carcinoma (RCC). However, clinically valid biomarkers of therapeutic outcome are lacking. We investigated the role of interleukin-10 (IL-10) as a predict…
View article: PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors Open
Purpose: Immune-checkpoint inhibitors have shown therapeutic efficacy in various malignant diseases. However, anti-programmed death (PD)-1 therapy has not shown clinical efficacy in multiple myeloma. Experimental Design: Bone marrow (BM) m…
View article: VEGF-A drives TOX-dependent T cell exhaustion in anti–PD-1–resistant microsatellite stable colorectal cancers
VEGF-A drives TOX-dependent T cell exhaustion in anti–PD-1–resistant microsatellite stable colorectal cancers Open
VEGF-A drives T cell exhaustion via TOX-dependent transcriptional programming in microsatellite stable colorectal cancers.